{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:15:16Z","timestamp":1792188916487,"version":"4.4.0"},"reference-count":398,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed\/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).<\/jats:p>","DOI":"10.6004\/jnccn.2026.0001","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:58:32Z","timestamp":1767880712000},"source":"Crossref","is-referenced-by-count":25,"title":["Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"24","author":[{"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Adekola","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Campagnaro","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Derman","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Devarakonda","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Elsedawy","sequence":"additional","affiliation":[{"name":"St. Jude Children's Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Godara","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Godby","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larson","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Omel","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna R.","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women's Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sherbenou","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya Nina","family":"Varshavsky-Yanovsky","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Vogl","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Christine","family":"Ye","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kovach","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Cancer stat facts: myeloma","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: myeloma. Accessed December 1, 2025. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B3","series-title":"BMC Public Health","first-page":"1054","article-title":"Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021","volume":"25","author":"Diao X","year":"2025","unstructured":"Diao X, Ben T, Cheng S, Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health 2025;25:1054."},{"key":"B4","series-title":"Mayo Clin Proc","first-page":"21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle RA","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21\u201333."},{"key":"B5","series-title":"Blood","first-page":"785","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri A","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785\u2013789."},{"key":"B6","series-title":"Blood","first-page":"4908","article-title":"Appraisal of immunoglobulin free light chain as a marker of response","volume":"111","author":"Dispenzieri A","year":"2008","unstructured":"Dispenzieri A, Zhang L, Katzmann JA, Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111:4908\u20134915."},{"key":"B7","series-title":"Leukemia","first-page":"215","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri A","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G, International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215\u2013224."},{"key":"B8","series-title":"J Cancer Res Clin Oncol","first-page":"477","article-title":"\u2018Light-chain escape-multiple myeloma\u2019 \u2013 an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring","volume":"135","author":"Kuhnemund A","year":"2009","unstructured":"Kuhnemund A, Liebisch P, Bauchmuller K, \u2018Light-chain escape-multiple myeloma\u2019 \u2013 an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009;135:477\u2013484."},{"key":"B9","series-title":"Leukemia","first-page":"1467","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie BG","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467\u20131473."},{"key":"B10","series-title":"Blood","first-page":"3941","article-title":"Flow cytometric immunophenotyping for hematologic neoplasms","volume":"111","author":"Craig FE","year":"2008","unstructured":"Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111:3941\u20133967."},{"key":"B11","series-title":"Haematologica","first-page":"1599","article-title":"Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients","volume":"94","author":"Paiva B","year":"2009","unstructured":"Paiva B, Vidriales MB, Perez JJ, Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009;94:1599\u20131602."},{"key":"B12","series-title":"Blood","first-page":"4235","article-title":"An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma","volume":"112","author":"Xiong W","year":"2008","unstructured":"Xiong W, Wu X, Starnes S, An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235\u20134246."},{"key":"B13","series-title":"Blood","first-page":"802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach J","year":"1998","unstructured":"Drach J, Ackermann J, Fritz E, Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802\u2013809."},{"key":"B14","series-title":"Blood","first-page":"3489","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau H","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489\u20133495."},{"key":"B15","series-title":"Blood","first-page":"2837","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz MA","year":"2005","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837\u20132840."},{"key":"B16","series-title":"Leukemia","first-page":"143","article-title":"Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis","volume":"21","author":"Gutierrez NC","year":"2007","unstructured":"Gutierrez NC, Castellanos MV, Martin ML, Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143\u2013150."},{"key":"B17","series-title":"Haematologica","first-page":"1221","article-title":"The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance","volume":"95","author":"Ross FM","year":"2010","unstructured":"Ross FM, Chiecchio L, Dagrada G, The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 2010;95:1221\u20131225."},{"key":"B18","series-title":"Haematologica","first-page":"1272","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross FM","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 2012;97:1272\u20131277."},{"key":"B19","series-title":"Blood","first-page":"1724","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura I","year":"2006","unstructured":"Hanamura I, Stewart JP, Huang Y, Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724\u20131732."},{"key":"B20","series-title":"Cancer Cell","first-page":"313","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco DR","year":"2006","unstructured":"Carrasco DR, Tonon G, Huang Y, High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313\u2013325."},{"key":"B21","series-title":"Br J Haematol","first-page":"729","article-title":"Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma","volume":"130","author":"Rosinol L","year":"2005","unstructured":"Rosinol L, Carrio A, Blade J, Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol 2005;130:729\u2013732."},{"key":"B22","series-title":"Mayo Clin Proc","first-page":"323","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri A","year":"2007","unstructured":"Dispenzieri A, Rajkumar SV, Gertz MA, Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323\u2013341."},{"key":"B23","series-title":"Mayo Clin Proc","first-page":"1095","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar SK","year":"2009","unstructured":"Kumar SK, Mikhael JR, Buadi FK, Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84:1095\u20131110."},{"key":"B24","series-title":"J Clin Oncol","first-page":"3406","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D\u2019Agostino M","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol 2022;40:3406\u20133418."},{"key":"B25","series-title":"J Clin Oncol","first-page":"2739","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau H","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol 2025;43:2739\u20132751."},{"key":"B26","series-title":"Blood","first-page":"Abstract 4468","article-title":"Findings of whole body computed tomography compared to conventional skeletal survey in patients with monoclonal plasma cell disorders - a study of the International Myeloma Working Group","volume":"128","author":"Hillengass J","year":"2016","unstructured":"Hillengass J, Moulopoulos LA, Delorme S, Findings of whole body computed tomography compared to conventional skeletal survey in patients with monoclonal plasma cell disorders - a study of the International Myeloma Working Group. Blood 2016;128:Abstract 4468."},{"key":"B27","series-title":"Eur Radiol","first-page":"51","article-title":"Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma","volume":"18","author":"Kropil P","year":"2008","unstructured":"Kropil P, Fenk R, Fritz LB, Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol 2008;18:51\u201358."},{"key":"B28","series-title":"Cancer Invest","first-page":"206","article-title":"Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey","volume":"31","author":"Princewill K","year":"2013","unstructured":"Princewill K, Kyere S, Awan O, Mulligan M. Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Invest 2013;31:206\u2013211."},{"key":"B29","series-title":"Eur J Nucl Med Mol Imaging","first-page":"525","article-title":"Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results","volume":"33","author":"Nanni C","year":"2006","unstructured":"Nanni C, Zamagni E, Farsad M, Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006;33:525\u2013531."},{"key":"B30","series-title":"Blood Cancer J","first-page":"e364","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","author":"Siontis B","year":"2015","unstructured":"Siontis B, Kumar S, Dispenzieri A, Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J 2015;5:e364."},{"key":"B31","series-title":"Leukemia","first-page":"417","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni E","year":"2016","unstructured":"Zamagni E, Nanni C, Gay F, 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 2016;30:417\u2013422."},{"key":"B32","series-title":"J Clin Oncol","first-page":"1606","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass J","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber MA, Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28:1606\u20131610."},{"key":"B33","series-title":"Leukemia","first-page":"1902","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz M","year":"2014","unstructured":"Merz M, Hielscher T, Wagner B, Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014;28:1902\u20131908."},{"key":"B34","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"555","article-title":"Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma","volume":"17","author":"van Beers EH","year":"2017","unstructured":"van Beers EH, van Vliet MH, Kuiper R, Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2017;17:555\u2013562."},{"key":"B35","series-title":"Lancet Oncol","first-page":"e293","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Merlini G, Bridoux F, Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol 2023;24:e293\u2013311."},{"key":"B36","series-title":"Lancet Oncol","first-page":"e538","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538\u2013548."},{"key":"B37","series-title":"Blood","first-page":"971","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau C","year":"2016","unstructured":"Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood 2016;127:971\u2013976."},{"key":"B38","series-title":"Haematologica","first-page":"1099","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition","volume":"102","author":"Granell M","year":"2017","unstructured":"Granell M, Calvo X, Garcia-Guinon A, Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 2017;102:1099\u20131104."},{"key":"B39","series-title":"J Clin Oncol","first-page":"3412","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp PR","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, International staging system for multiple myeloma. J Clin Oncol 2005;23:3412\u20133420."},{"key":"B40","series-title":"J Clin Oncol","first-page":"2863","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo A","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33:2863\u20132869."},{"key":"B41","series-title":"CA Cancer J Clin","first-page":"202","article-title":"Cancer statistics for African American\/Black people 2022","volume":"72","author":"Giaquinto AN","year":"2022","unstructured":"Giaquinto AN, Miller KD, Tossas KY, Cancer statistics for African American\/Black people 2022. CA Cancer J Clin 2022;72:202\u2013229."},{"key":"B42","article-title":"SEER Cancer Statistics Review, 1975-2016","author":"Howlader N","unstructured":"Howlader N, Noone A, Krapcho M, SEER Cancer Statistics Review, 1975-2016. Accessed December 1, 2025. Available at: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2016\/index.html"},{"key":"B43","series-title":"Blood Adv","first-page":"251","article-title":"Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy","volume":"8","author":"Peres LC","year":"2024","unstructured":"Peres LC, Oswald LB, Dillard CM, Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv 2024;8:251\u2013259."},{"key":"B44","series-title":"Blood Adv","first-page":"317","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz LE","year":"2023","unstructured":"Merz LE, Story CM, Osei MA, Absolute neutrophil count by Duffy status among healthy Black and African American adults. Blood Adv 2023;7:317\u2013320."},{"key":"B45","series-title":"Blood Adv","first-page":"1452","article-title":"Characterization of the phenotypic consequences of the Duffy-null genotype","volume":"9","author":"Hysong MR","year":"2025","unstructured":"Hysong MR, Shuey MM, Huffman JE, Characterization of the phenotypic consequences of the Duffy-null genotype. Blood Adv 2025;9:1452\u20131462."},{"key":"B46","series-title":"Semin Hematol","first-page":"38","article-title":"Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters","volume":"62","author":"Merz L","year":"2025","unstructured":"Merz L, Hartley-Brown M, Achebe M, Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters. Semin Hematol 2025;62:38\u201342."},{"key":"B47","series-title":"Lancet Reg Health Am","first-page":"100252","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"Turner BE","year":"2022","unstructured":"Turner BE, Steinberg JR, Weeks BT, Race\/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am 2022;11:100252."},{"key":"B48","series-title":"Blood","first-page":"3416","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder CB","year":"2010","unstructured":"Reeder CB, Reece DE, Kukreti V, Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115:3416\u20133417."},{"key":"B49","series-title":"Lancet Oncol","first-page":"431","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau P","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431\u2013440."},{"key":"B50","series-title":"Haematologica","first-page":"1925","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf B","year":"2012","unstructured":"Arnulf B, Pylypenko H, Grosicki S, Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97:1925\u20131928."},{"key":"B51","series-title":"Lancet Haematol","first-page":"e370","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos MV","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 2020;7:e370\u2013380."},{"key":"B52","series-title":"Blood","first-page":"Abstract 5557","article-title":"Assessing steroid toxicity in the elderly with multiple myeloma","volume":"134","author":"Nair V","year":"2019","unstructured":"Nair V, Mohammed H, Mahmood S, Assessing steroid toxicity in the elderly with multiple myeloma. Blood 2019;134(Suppl 1):Abstract 5557."},{"key":"B53","series-title":"Blood","first-page":"3027","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca A","year":"2021","unstructured":"Larocca A, Bonello F, Gaidano G, Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021;137:3027\u20133036."},{"key":"B54","series-title":"N Engl J Med","first-page":"301","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld P","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390:301\u2013313."},{"key":"B55","series-title":"Lancet Haematol","first-page":"e825","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation- eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees PM","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation- eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023;10:e825\u2013837."},{"key":"B56","series-title":"Blood Cancer J","first-page":"37","article-title":"Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Souto Filho JTD","year":"2025","unstructured":"Souto Filho JTD, Cantadori LO, Crusoe EQ, Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer J 2025;15:37."},{"key":"B57","series-title":"Lancet Haematol","first-page":"e810","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt H","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022;9:e810\u2013821."},{"key":"B58","series-title":"J Clin Oncol","first-page":"1279","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai EK","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E, Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2025;43:1279\u20131288."},{"key":"B59","series-title":"Blood","first-page":"679","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson PG","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679\u2013686."},{"key":"B60","series-title":"J Clin Oncol","first-page":"2712","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome","volume":"32","author":"Roussel M","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014;32:2712\u20132717."},{"key":"B61","series-title":"Blood","first-page":"4375","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar S","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375\u20134382."},{"key":"B62","series-title":"Lancet","first-page":"519","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open- label, phase 3 trial","volume":"389","author":"Durie BGM","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open- label, phase 3 trial. Lancet 2017;389:519\u2013527."},{"key":"B63","series-title":"Blood Cancer J","first-page":"53","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie BGM","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J 2020;10:53."},{"key":"B64","series-title":"Eur J Haematol","first-page":"110","article-title":"The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"104","author":"Okazuka K","year":"2020","unstructured":"Okazuka K, Ishida T, Nashimoto J, The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Eur J Haematol 2020;104:110\u2013115."},{"key":"B65","series-title":"Blood","first-page":"1801","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak AJ","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801\u20131809."},{"key":"B66","series-title":"J Clin Oncol","first-page":"Abstract e18568","article-title":"Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients","volume":"30","author":"Korde N","year":"2012","unstructured":"Korde N, Zingone A, Kwok M, Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. J Clin Oncol 2012;30:Abstract e18568."},{"key":"B67","series-title":"JAMA Oncol","first-page":"746","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde N","year":"2015","unstructured":"Korde N, Roschewski M, Zingone A, Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 2015;1:746\u2013754."},{"key":"B68","series-title":"Blood","first-page":"2513","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","volume":"136","author":"Jasielec JK","year":"2020","unstructured":"Jasielec JK, Kubicki T, Raje N, Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood 2020;136:2513\u20132523."},{"key":"B69","series-title":"Lancet Oncol","first-page":"1317","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar SK","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD, Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21:1317\u20131330."},{"key":"B70","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"S307","article-title":"MM-347: Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant: the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial","volume":"20","author":"Facon T","year":"2020","unstructured":"Facon T, Venner CP, Bahlis NJ, MM-347: Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant: the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial. Clin Lymphoma Myeloma Leuk 2020;20(Suppl 1):S307\u2013308."},{"key":"B71","series-title":"Blood","first-page":"3616","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon T","year":"2021","unstructured":"Facon T, Venner CP, Bahlis NJ, Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2021;137:3616\u20133628."},{"key":"B72","series-title":"JAMA Oncol","first-page":"862","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren O","year":"2021","unstructured":"Landgren O, Hultcrantz M, Diamond B, Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol 2021;7:862\u2013868."},{"key":"B73","series-title":"Blood Cancer J","first-page":"87","article-title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant","volume":"14","author":"Derman BA","year":"2024","unstructured":"Derman BA, Cooperrider J, Rosenblatt J, Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J 2024;14:87."},{"key":"B74","series-title":"J Clin Oncol","first-page":"2901","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa LJ","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2022;40:2901\u20132912."},{"key":"B75","series-title":"Lancet Haematol","first-page":"e890","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa LJ","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol 2023;10:e890\u2013901."},{"key":"B76","series-title":"Blood","first-page":"2029","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau C","year":"2024","unstructured":"Touzeau C, Perrot A, Hulin C, Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 2024;143:2029\u20132036."},{"key":"B77","series-title":"Blood","first-page":"Abstract 4","article-title":"Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay F","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood 2023;142:Abstract 4."},{"key":"B78","series-title":"J Clin Oncol","first-page":"26","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt LB","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol 2024;42:26\u201337."},{"key":"B79","series-title":"N Engl J Med","first-page":"425","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot A","year":"2025","unstructured":"Perrot A, Lambert J, Hulin C, Measurable residual disease-guided therapy in newly diagnosed myeloma. N Engl J Med 2025;393:425\u2013437."},{"key":"B80","series-title":"Leukemia","first-page":"1337","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder CB","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V, Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337\u20131341."},{"key":"B81","series-title":"J Clin Oncol","first-page":"Abstract 8516","article-title":"Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial","volume":"27","author":"Knop S","year":"2009","unstructured":"Knop S, Liebisch P, Wandt H, Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial. J Clin Oncol 2009;27(Suppl):Abstract 8516."},{"key":"B82","series-title":"Br J Haematol","first-page":"563","article-title":"Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma","volume":"167","author":"Reeder CB","year":"2014","unstructured":"Reeder CB, Reece DE, Kukreti V, Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol 2014;167:563\u2013565."},{"key":"B83","series-title":"Blood","first-page":"63","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen S","year":"2014","unstructured":"Bringhen S, Petrucci MT, Larocca A, Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014;124:63\u201369."},{"key":"B84","series-title":"Leukemia","first-page":"979","article-title":"Phase 1\/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma","volume":"32","author":"Bringhen S","year":"2018","unstructured":"Bringhen S, D\u2019Agostino M, De Paoli L, Phase 1\/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia 2018;32:979\u2013985."},{"key":"B85","series-title":"Haematologica","first-page":"1640","article-title":"Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I\/II studies","volume":"104","author":"Bringhen S","year":"2019","unstructured":"Bringhen S, Mina R, Petrucci MT, Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I\/II studies. Haematologica 2019;104:1640\u20131647."},{"key":"B86","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"433","article-title":"A multicenter, open-label, phase 1b study of carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients (CHAMPION-2)","volume":"17","author":"Boccia RV","year":"2017","unstructured":"Boccia RV, Bessudo A, Agajanian R, A multicenter, open-label, phase 1b study of carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients (CHAMPION-2). Clin Lymphoma Myeloma Leuk 2017;17:433\u2013437."},{"key":"B87","series-title":"Eur J Cancer","first-page":"89","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Grosicki S, J\u0119drzejczak WW, All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89\u201398."},{"key":"B88","series-title":"Lancet Oncol","first-page":"1503","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar SK","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol 2014;15:1503\u20131512."},{"key":"B89","series-title":"Br J Haematol","first-page":"492","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer H","year":"2019","unstructured":"Yimer H, Melear J, Faber E, Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 2019;185:492\u2013502."},{"key":"B90","series-title":"Br J Haematol","first-page":"176","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie B","year":"2007","unstructured":"Barlogie B, Anaissie E, van Rhee F, Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176\u2013185."},{"key":"B91","series-title":"Lancet Oncol","first-page":"1582","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon T","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:1582\u20131596."},{"key":"B92","series-title":"Leukemia","first-page":"942","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon T","year":"2025","unstructured":"Facon T, Moreau P, Weisel K, Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia 2025;39:942\u2013950."},{"key":"B93","series-title":"Lancet Oncol","first-page":"1323","article-title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","volume":"26","author":"Manier S","year":"2025","unstructured":"Manier S, Lambert J, Hulin C, Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial. Lancet Oncol 2025;26:1323\u20131333."},{"key":"B94","series-title":"Nat Med","first-page":"1366","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani SZ","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med 2025;31:1366\u20131202."},{"key":"B95","series-title":"N Engl J Med","first-page":"1597","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon T","year":"2024","unstructured":"Facon T, Dimopoulos M-A, Leleu XP, Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;391:1597\u20131609."},{"key":"B96","series-title":"Nat Med","first-page":"2235","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu X","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med 2024;30:2235\u20132241."},{"key":"B97","series-title":"Haematologica","first-page":"e162","article-title":"Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma","volume":"99","author":"Dytfeld D","year":"2014","unstructured":"Dytfeld D, Jasielec J, Griffith KA, Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica 2014;99:e162\u2013164."},{"key":"B98","series-title":"Blood","first-page":"Abstract 77","article-title":"Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232","volume":"110","author":"Zonder JA","year":"2007","unstructured":"Zonder JA, Crowley J, Hussein MA, Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232. Blood 2007;110:Abstract 77."},{"key":"B99","series-title":"Lancet Oncol","first-page":"29","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar SV","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29\u201337."},{"key":"B100","series-title":"N Engl J Med","first-page":"906","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker L","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906\u2013917."},{"key":"B101","series-title":"N Engl J Med","first-page":"1782","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal M","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782\u20131791."},{"key":"B102","series-title":"N Engl J Med","first-page":"1770","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy PL","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770\u20131781."},{"key":"B103","series-title":"Blood","first-page":"1597","article-title":"Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance","volume":"120","author":"Usmani SZ","year":"2012","unstructured":"Usmani SZ, Sexton R, Hoering A, Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012;120:1597\u20131600."},{"key":"B104","series-title":"Lancet Oncol","first-page":"333","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta- analysis of individual patient data","volume":"15","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta- analysis of individual patient data. Lancet Oncol 2014;15:333\u2013342."},{"key":"B105","series-title":"Haematologica","first-page":"363","article-title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma","volume":"101","author":"Dimopoulos MA","year":"2016","unstructured":"Dimopoulos MA, Cheung MC, Roussel M, Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica 2016;101:363\u2013370."},{"key":"B106","series-title":"J Clin Oncol","first-page":"3609","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin C","year":"2016","unstructured":"Hulin C, Belch A, Shustik C, Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol 2016;34:3609\u20133617."},{"key":"B107","series-title":"Blood","first-page":"Abstract 5751","article-title":"Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant eligible multiple myeloma patients","volume":"124","author":"Zepeda J","year":"2014","unstructured":"Zepeda J, HV, Duggan P, Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant eligible multiple myeloma patients. Blood 2014;124:Abstract 5751."},{"key":"B108","series-title":"J Clin Oncol","first-page":"3921","article-title":"Community-based Phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky R","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Community-based Phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol 2015;33:3921\u20133929."},{"key":"B109","series-title":"Blood","first-page":"Abstract 478","article-title":"Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study","volume":"118","author":"Niesvizky R","year":"2011","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. Blood 2011;118:Abstract 478."},{"key":"B110","series-title":"Br J Haematol","first-page":"222","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell EK","year":"2018","unstructured":"O\u2019Donnell EK, Laubach JP, Yee AJ, A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 2018;182:222\u2013230."},{"key":"B111","series-title":"Lancet Oncol","first-page":"801","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:801\u2013812."},{"key":"B112","series-title":"Blood Adv","first-page":"3721","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16","volume":"8","author":"Mollee P","year":"2024","unstructured":"Mollee P, Reynolds J, Janowski W, Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16. Blood Adv 2024;8:3721\u20133730."},{"key":"B113","series-title":"Blood Adv","first-page":"3129","article-title":"Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury","volume":"9","author":"Kim EB","year":"2025","unstructured":"Kim EB, Malespini JE, Lei M, Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury. Blood Adv 2025;9:3129\u20133135."},{"key":"B114","series-title":"Future Oncol","first-page":"131","article-title":"In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma","volume":"20","author":"Rifkin RM","year":"2024","unstructured":"Rifkin RM, Costello CL, Birhiray RE, In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. Future Oncol 2024;20:131\u2013143."},{"key":"B115","series-title":"Blood Cancer J","first-page":"147","article-title":"In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management","volume":"13","author":"Rifkin RM","year":"2023","unstructured":"Rifkin RM, Girnius SK, Noga SJ, In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management. Blood Cancer J 2023;13:147."},{"key":"B116","series-title":"Am J Hematol","first-page":"640","article-title":"Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial","volume":"86","author":"Kumar SK","year":"2011","unstructured":"Kumar SK, Lacy MQ, Hayman SR, Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011;86:640\u2013645."},{"key":"B117","series-title":"Blood","first-page":"Abstract 540","article-title":"Lenalidomide combined with cyclophosphamide and dexamethasone is effective and well tolerated induction treatment for newly diagnosed myeloma patients of all ages","volume":"122","author":"Pawlyn C","year":"2013","unstructured":"Pawlyn C, Brioli A, Gregory W, Lenalidomide combined with cyclophosphamide and dexamethasone is effective and well tolerated induction treatment for newly diagnosed myeloma patients of all ages. Blood 2013;122:Abstract 540."},{"key":"B118","series-title":"Haematologica","first-page":"1957","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson GH","year":"2021","unstructured":"Jackson GH, Davies FE, Pawlyn C, Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica 2021;106:1957\u20131967."},{"key":"B119","series-title":"Am J Hematol","first-page":"57","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar SV.","year":"2011","unstructured":"Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:57\u201365."},{"key":"B120","series-title":"J Clin Oncol","first-page":"587","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;32:587\u2013600."},{"key":"B121","series-title":"Lancet Oncol","first-page":"e328","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328\u2013346."},{"key":"B122","series-title":"J Clin Oncol","first-page":"1121","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker R","year":"2007","unstructured":"Walker R, Barlogie B, Haessler J, Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007;25:1121\u20131128."},{"key":"B123","series-title":"Blood","first-page":"2068","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel TB","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009;114:2068\u20132076."},{"key":"B124","series-title":"Clin Cancer Res","first-page":"4384","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni E","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 2015;21:4384\u20134390."},{"key":"B125","series-title":"J Clin Oncol","first-page":"2911","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study","volume":"35","author":"Moreau P","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol 2017;35:2911\u20132918."},{"key":"B126","series-title":"Leukemia","first-page":"1446","article-title":"Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn C","year":"2016","unstructured":"Pawlyn C, Fowkes L, Otero S, Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia 2016;30:1446\u20131448."},{"key":"B127","series-title":"Blood","first-page":"30","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche L","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 2017;130:30\u201334."},{"key":"B128","series-title":"Leukemia","first-page":"1713","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche L","year":"2019","unstructured":"Rasche L, Alapat D, Kumar M, Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 2019;33:1713\u20131722."},{"key":"B129","series-title":"JAMA Oncol","first-page":"28","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi NC","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 2017;3:28\u201335."},{"key":"B130","series-title":"N Engl J Med","first-page":"91","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal M","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91\u201397."},{"key":"B131","series-title":"N Engl J Med","first-page":"1875","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child JA","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875\u20131883."},{"key":"B132","series-title":"J Clin Oncol","first-page":"929","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie B","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929\u2013936."},{"key":"B133","series-title":"Blood","first-page":"731","article-title":"Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial","volume":"99","author":"Moreau P","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731\u2013735."},{"key":"B134","series-title":"J Clin Oncol","first-page":"9227","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand JP","year":"2005","unstructured":"Fermand JP, Katsahian S, Divine M, High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227\u20139233."},{"key":"B135","series-title":"N Engl J Med","first-page":"895","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371:895\u2013905."},{"key":"B136","series-title":"J Clin Oncol","first-page":"4621","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau JL","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621\u20134629."},{"key":"B137","series-title":"Blood","first-page":"9","article-title":"Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo M","year":"2012","unstructured":"Cavo M, Pantani L, Petrucci MT, Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9\u201319."},{"key":"B138","series-title":"N Engl J Med","first-page":"1311","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal M","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376:1311\u20131320."},{"key":"B139","series-title":"N Engl J Med","first-page":"132","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson PG","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387:132\u2013147."},{"key":"B140","series-title":"N Engl J Med","first-page":"2495","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal M","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495\u20132502."},{"key":"B141","series-title":"J Clin Oncol","first-page":"2434","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo M","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434\u20132441."},{"key":"B142","series-title":"Blood","first-page":"Abstract 2545","article-title":"Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial","volume":"106","author":"Sonneveld P","year":"2005","unstructured":"Sonneveld P, van der Holt B, Vellenga E, Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial. Blood 2005;106:Abstract 2545."},{"key":"B143","series-title":"Br J Haematol","first-page":"731","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai EK","year":"2016","unstructured":"Mai EK, Benner A, Bertsch U, Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol 2016;173:731\u2013741."},{"key":"B144","series-title":"J Clin Oncol","first-page":"1209","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences","volume":"28","author":"Barlogie B","year":"2010","unstructured":"Barlogie B, Attal M, Crowley J, Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010;28:1209\u20131214."},{"key":"B145","series-title":"Blood","first-page":"Abstract LBA-1","article-title":"Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem auto-HCT with Len maintenance (TAM) and AutoHCT with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 \u2013 StaMINA Trial)","volume":"128","author":"Stadtmauer A","year":"2016","unstructured":"Stadtmauer A, Pasquini M, Blackwell B, Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem auto-HCT with Len maintenance (TAM) and AutoHCT with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 \u2013 StaMINA Trial). Blood 2016;128:Abstract LBA-1."},{"key":"B146","article-title":"Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial","author":"Petrucci T","year":"2016","unstructured":"Petrucci T, Raimondo FD, Zamagni E, Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial. Presented at the 58th ASH Annual Meeting; December 3\u20136, 2016; San Diego, California."},{"key":"B147","series-title":"J Clin Oncol","first-page":"589","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer EA","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol 2019;37:589\u2013597."},{"key":"B148","series-title":"Biol Blood Marrow Transplant","first-page":"1638","article-title":"Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry","volume":"17","author":"Cook G","year":"2011","unstructured":"Cook G, Liakopoulou E, Pearce R, Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011;17:1638\u20131645."},{"key":"B149","series-title":"Bone Marrow Transplant","first-page":"417","article-title":"Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin RL","year":"2009","unstructured":"Olin RL, Vogl DT, Porter DL, Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417\u2013422."},{"key":"B150","series-title":"Leuk Lymphoma","first-page":"1442","article-title":"Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma","volume":"50","author":"Burzynski JA","year":"2009","unstructured":"Burzynski JA, Toro JJ, Patel RC, Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009;50:1442\u20131447."},{"key":"B151","series-title":"Haematologica","first-page":"141","article-title":"The role of second autografts in the management of myeloma at first relapse","volume":"91","author":"Alvares CL","year":"2006","unstructured":"Alvares CL, Davies FE, Horton C, The role of second autografts in the management of myeloma at first relapse. Haematologica 2006;91:141\u2013142."},{"key":"B152","series-title":"Leuk Lymphoma","first-page":"1455","article-title":"Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation","volume":"52","author":"Fenk R","year":"2011","unstructured":"Fenk R, Liese V, Neubauer F, Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011;52:1455\u20131462."},{"key":"B153","series-title":"Lancet Oncol","first-page":"874","article-title":"High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial","volume":"15","author":"Cook G","year":"2014","unstructured":"Cook G, Williams C, Brown JM, High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:874\u2013885."},{"key":"B154","series-title":"Lancet Haematol","first-page":"e340","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook G","year":"2016","unstructured":"Cook G, Ashcroft AJ, Cairns DA, The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol 2016;3:e340\u2013351."},{"key":"B155","series-title":"Bone Marrow Transplant","first-page":"413","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"Kumar S","year":"2008","unstructured":"Kumar S, Mahmood ST, Lacy MQ, Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008;42:413\u2013420."},{"key":"B156","series-title":"Eur J Haematol","first-page":"209","article-title":"Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994\u20132004","volume":"85","author":"Vangsted AJ","year":"2010","unstructured":"Vangsted AJ, Klausen TW, Andersen NF, Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994\u20132004. Eur J Haematol 2010;85:209\u2013216."},{"key":"B157","series-title":"Leukemia","first-page":"986","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"Kumar SK","year":"2018","unstructured":"Kumar SK, Dispenzieri A, Fraser R, Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 2018;32:986\u2013995."},{"key":"B158","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"445","article-title":"Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma","volume":"20","author":"Kastritis E","year":"2020","unstructured":"Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma. Clin Lymphoma Myeloma Leuk 2020;20:445\u2013452."},{"key":"B159","series-title":"Br J Haematol","first-page":"551","article-title":"Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma","volume":"193","author":"Bygrave C","year":"2021","unstructured":"Bygrave C, Pawlyn C, Davies F, Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol 2021;193:551\u2013555."},{"key":"B160","series-title":"Leuk Lymphoma","first-page":"2200","article-title":"Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation","volume":"54","author":"Auner HW","year":"2013","unstructured":"Auner HW, Szydlo R, Rone A, Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma 2013;54:2200\u20132204."},{"key":"B161","series-title":"Biol Blood Marrow Transplant","first-page":"773","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival","volume":"18","author":"Jimenez-Zepeda VH","year":"2012","unstructured":"Jimenez-Zepeda VH, Mikhael J, Winter A, Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012;18:773\u2013779."},{"key":"B162","series-title":"Cancer","first-page":"2438","article-title":"Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients","volume":"119","author":"Sellner L","year":"2013","unstructured":"Sellner L, Heiss C, Benner A, Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer 2013;119:2438\u20132446."},{"key":"B163","series-title":"Cancer","first-page":"3549","article-title":"Durable remission with salvage second autotransplants in patients with multiple myeloma","volume":"118","author":"Shah N","year":"2012","unstructured":"Shah N, Ahmed F, Bashir Q, Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012;118:3549\u20133555."},{"key":"B164","series-title":"Semin Oncol","first-page":"74","article-title":"High-dose therapy in multiple myeloma and primary amyloidosis: an overview","volume":"26","author":"Kyle RA.","year":"1999","unstructured":"Kyle RA. High-dose therapy in multiple myeloma and primary amyloidosis: an overview. Semin Oncol 1999;26:74\u201383."},{"key":"B165","series-title":"Lancet Oncol","first-page":"293","article-title":"Management of multiple myeloma: a systematic review and critical appraisal of published studies","volume":"4","author":"Kumar A","year":"2003","unstructured":"Kumar A, Loughran T, Alsina M, Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003;4:293\u2013304."},{"key":"B166","series-title":"Biol Blood Marrow Transplant","first-page":"4","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review","volume":"9","author":"Hahn T","year":"2003","unstructured":"Hahn T, Wingard JR, Anderson KC, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 2003;9:4\u201337."},{"key":"B167","series-title":"Bone Marrow Transplant","first-page":"923","article-title":"Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives","volume":"34","author":"Zeiser R","year":"2004","unstructured":"Zeiser R, Bertz H, Spyridonidis A, Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant 2004;34:923\u2013928."},{"key":"B168","series-title":"Bone Marrow Transplant","first-page":"1135","article-title":"Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"37","author":"van de Donk NW","year":"2006","unstructured":"van de Donk NW, Kroger N, Hegenbart U, Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1135\u20131141."},{"key":"B169","series-title":"Blood","first-page":"4362","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst HM","year":"2004","unstructured":"Lokhorst HM, Wu K, Verdonck LF, The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103:4362\u20134364."},{"key":"B170","series-title":"J Clin Oncol","first-page":"3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst HM","year":"2000","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031\u20133037."},{"key":"B171","series-title":"Blood","first-page":"4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst HM","year":"1997","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997;90:4206\u20134211."},{"key":"B172","series-title":"Bone Marrow Transplant","first-page":"1179","article-title":"Donor leukocyte infusions for multiple myeloma","volume":"26","author":"Salama M","year":"2000","unstructured":"Salama M, Nevill T, Marcellus D, Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179\u20131184."},{"key":"B173","series-title":"Blood","first-page":"1196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot G","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196\u20131198."},{"key":"B174","series-title":"Leukemia","first-page":"659","article-title":"Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma","volume":"18","author":"Ayuk F","year":"2004","unstructured":"Ayuk F, Shimoni A, Nagler A, Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004;18:659\u2013662."},{"key":"B175","series-title":"Blood Adv","first-page":"5988","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi NC","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 2020;4:5988\u20135999."},{"key":"B176","series-title":"J Clin Oncol","first-page":"2540","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX study","volume":"31","author":"Rawstron AC","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM, Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX study. J Clin Oncol 2013;31:2540\u20132547."},{"key":"B177","series-title":"Biol Blood Marrow Transplant","first-page":"S4","article-title":"Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study","volume":"25","author":"Hahn TE","year":"2019","unstructured":"Hahn TE, Wallace PK, Fraser R, Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study. Biol Blood Marrow Transplant 2019;25:S4\u20136."},{"key":"B178","series-title":"Eur J Haematol","first-page":"416","article-title":"Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma","volume":"85","author":"Putkonen M","year":"2010","unstructured":"Putkonen M, Kairisto V, Juvonen V, Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 2010;85:416\u2013423."},{"key":"B179","series-title":"Lancet Haematol","first-page":"e431","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein SA","year":"2017","unstructured":"Holstein SA, Jung SH, Richardson PG, Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 2017;4:e431\u2013442."},{"key":"B180","series-title":"J Clin Oncol","first-page":"3279","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy PL","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 2017;35:3279\u20133289."},{"key":"B181","series-title":"Blood","first-page":"2413","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers E","year":"2011","unstructured":"Kneppers E, van der Holt B, Kersten MJ, Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011;118:2413\u20132419."},{"key":"B182","series-title":"Biol Blood Marrow Transplant","first-page":"1183","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina M","year":"2014","unstructured":"Alsina M, Becker PS, Zhong X, Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:1183\u20131189."},{"key":"B183","series-title":"N Engl J Med","first-page":"1759","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo A","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759\u20131769."},{"key":"B184","series-title":"Leukemia","first-page":"1853","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt H","year":"2020","unstructured":"Goldschmidt H, Mai EK, Durig J, Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 2020;34:1853\u20131865."},{"key":"B185","series-title":"Ann Oncol","first-page":"228","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto P","year":"2017","unstructured":"Musto P, Anderson KC, Attal M, Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017;28:228\u2013245."},{"key":"B186","series-title":"Lancet Oncol","first-page":"1705","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay F","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021;22:1705\u20131720."},{"key":"B187","series-title":"Blood","first-page":"Abstract 79","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 24 months of maintenance","volume":"138","author":"Laubach JP","year":"2021","unstructured":"Laubach JP, Kaufman JL, Sborov DW, Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 24 months of maintenance. Blood 2021;138(Suppl 1):Abstract 79."},{"key":"B188","series-title":"J Clin Oncol","first-page":"Abstract 7501","article-title":"Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained MRD negativity in the phase 3 PERSEUS trial","volume":"43","author":"Moreau P","year":"2025","unstructured":"Moreau P, Sonneveld P, Einseke H, et al. Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained MRD negativity in the phase 3 PERSEUS trial. J Clin Oncol 2025;43(Suppl):Abstract 7501."},{"key":"B189","series-title":"Blood","first-page":"300","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros A","year":"2025","unstructured":"Badros A, Foster L, Anderson LD, Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood 2025;145:300\u2013310."},{"key":"B190","series-title":"Leukemia","first-page":"690","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka AK","year":"2014","unstructured":"Nooka AK, Kaufman JL, Muppidi S, Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014;28:690\u2013693."},{"key":"B191","series-title":"J Clin Oncol","first-page":"1928","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph NS","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 2020;38:1928\u20131937."},{"key":"B192","series-title":"J Clin Oncol","first-page":"2946","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld P","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol 2012;30:2946\u20132955."},{"key":"B193","series-title":"Blood","first-page":"4647","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist UH","year":"2013","unstructured":"Mellqvist UH, Gimsing P, Hjertner O, Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013;121:4647\u20134654."},{"key":"B194","series-title":"Lancet Oncol","first-page":"1378","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau P","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:1378\u20131390."},{"key":"B195","series-title":"Lancet Oncol","first-page":"1003","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau P","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 2024;25:1003\u20131014."},{"key":"B196","series-title":"Lancet","first-page":"253","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393:253\u2013264."},{"key":"B197","series-title":"Leukemia","first-page":"3019","article-title":"Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma","volume":"34","author":"Goldschmidt H","year":"2020","unstructured":"Goldschmidt H, Dimopoulos MA, Rajkumar SV, Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia 2020;34:3019\u20133027."},{"key":"B198","series-title":"J Clin Oncol","first-page":"4030","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos MA","year":"2020","unstructured":"Dimopoulos MA, Spicka I, Quach H, Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol 2020;38:4030\u20134041."},{"key":"B199","series-title":"Blood","first-page":"Abstract 1656","article-title":"Interim analyses of overall survival (OS) from the TOURMALINE MM3 & MM4 studies of ixazomib maintenance following primary therapy in multiple myeloma (MM)","volume":"138","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Rajkumar SV, Lonial S, Interim analyses of overall survival (OS) from the TOURMALINE MM3 & MM4 studies of ixazomib maintenance following primary therapy in multiple myeloma (MM). Blood 2021;138(Suppl 1):Abstract 1656."},{"key":"B1","article-title":"Cancer stat facts: myeloma","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: myeloma. Accessed December 1, 2025. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B3","series-title":"BMC Public Health","first-page":"1054","article-title":"Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021","volume":"25","author":"Diao X","year":"2025","unstructured":"Diao X, Ben T, Cheng S, Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health 2025;25:1054."},{"key":"B4","series-title":"Mayo Clin Proc","first-page":"21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle RA","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21\u201333."},{"key":"B5","series-title":"Blood","first-page":"785","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri A","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785\u2013789."},{"key":"B6","series-title":"Blood","first-page":"4908","article-title":"Appraisal of immunoglobulin free light chain as a marker of response","volume":"111","author":"Dispenzieri A","year":"2008","unstructured":"Dispenzieri A, Zhang L, Katzmann JA, Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111:4908\u20134915."},{"key":"B7","series-title":"Leukemia","first-page":"215","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri A","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G, International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215\u2013224."},{"key":"B8","series-title":"J Cancer Res Clin Oncol","first-page":"477","article-title":"\u2018Light-chain escape-multiple myeloma\u2019 \u2013 an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring","volume":"135","author":"Kuhnemund A","year":"2009","unstructured":"Kuhnemund A, Liebisch P, Bauchmuller K, \u2018Light-chain escape-multiple myeloma\u2019 \u2013 an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009;135:477\u2013484."},{"key":"B9","series-title":"Leukemia","first-page":"1467","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie BG","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467\u20131473."},{"key":"B10","series-title":"Blood","first-page":"3941","article-title":"Flow cytometric immunophenotyping for hematologic neoplasms","volume":"111","author":"Craig FE","year":"2008","unstructured":"Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111:3941\u20133967."},{"key":"B11","series-title":"Haematologica","first-page":"1599","article-title":"Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients","volume":"94","author":"Paiva B","year":"2009","unstructured":"Paiva B, Vidriales MB, Perez JJ, Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009;94:1599\u20131602."},{"key":"B12","series-title":"Blood","first-page":"4235","article-title":"An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma","volume":"112","author":"Xiong W","year":"2008","unstructured":"Xiong W, Wu X, Starnes S, An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235\u20134246."},{"key":"B13","series-title":"Blood","first-page":"802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach J","year":"1998","unstructured":"Drach J, Ackermann J, Fritz E, Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802\u2013809."},{"key":"B14","series-title":"Blood","first-page":"3489","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau H","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489\u20133495."},{"key":"B15","series-title":"Blood","first-page":"2837","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz MA","year":"2005","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837\u20132840."},{"key":"B16","series-title":"Leukemia","first-page":"143","article-title":"Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis","volume":"21","author":"Gutierrez NC","year":"2007","unstructured":"Gutierrez NC, Castellanos MV, Martin ML, Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143\u2013150."},{"key":"B17","series-title":"Haematologica","first-page":"1221","article-title":"The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance","volume":"95","author":"Ross FM","year":"2010","unstructured":"Ross FM, Chiecchio L, Dagrada G, The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 2010;95:1221\u20131225."},{"key":"B18","series-title":"Haematologica","first-page":"1272","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross FM","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 2012;97:1272\u20131277."},{"key":"B19","series-title":"Blood","first-page":"1724","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura I","year":"2006","unstructured":"Hanamura I, Stewart JP, Huang Y, Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724\u20131732."},{"key":"B20","series-title":"Cancer Cell","first-page":"313","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco DR","year":"2006","unstructured":"Carrasco DR, Tonon G, Huang Y, High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313\u2013325."},{"key":"B21","series-title":"Br J Haematol","first-page":"729","article-title":"Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma","volume":"130","author":"Rosinol L","year":"2005","unstructured":"Rosinol L, Carrio A, Blade J, Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol 2005;130:729\u2013732."},{"key":"B22","series-title":"Mayo Clin Proc","first-page":"323","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri A","year":"2007","unstructured":"Dispenzieri A, Rajkumar SV, Gertz MA, Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323\u2013341."},{"key":"B23","series-title":"Mayo Clin Proc","first-page":"1095","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar SK","year":"2009","unstructured":"Kumar SK, Mikhael JR, Buadi FK, Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84:1095\u20131110."},{"key":"B24","series-title":"J Clin Oncol","first-page":"3406","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D\u2019Agostino M","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol 2022;40:3406\u20133418."},{"key":"B25","series-title":"J Clin Oncol","first-page":"2739","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau H","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol 2025;43:2739\u20132751."},{"key":"B26","series-title":"Blood","first-page":"Abstract 4468","article-title":"Findings of whole body computed tomography compared to conventional skeletal survey in patients with monoclonal plasma cell disorders - a study of the International Myeloma Working Group","volume":"128","author":"Hillengass J","year":"2016","unstructured":"Hillengass J, Moulopoulos LA, Delorme S, Findings of whole body computed tomography compared to conventional skeletal survey in patients with monoclonal plasma cell disorders - a study of the International Myeloma Working Group. Blood 2016;128:Abstract 4468."},{"key":"B27","series-title":"Eur Radiol","first-page":"51","article-title":"Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma","volume":"18","author":"Kropil P","year":"2008","unstructured":"Kropil P, Fenk R, Fritz LB, Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol 2008;18:51\u201358."},{"key":"B28","series-title":"Cancer Invest","first-page":"206","article-title":"Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey","volume":"31","author":"Princewill K","year":"2013","unstructured":"Princewill K, Kyere S, Awan O, Mulligan M. Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Invest 2013;31:206\u2013211."},{"key":"B29","series-title":"Eur J Nucl Med Mol Imaging","first-page":"525","article-title":"Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results","volume":"33","author":"Nanni C","year":"2006","unstructured":"Nanni C, Zamagni E, Farsad M, Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006;33:525\u2013531."},{"key":"B30","series-title":"Blood Cancer J","first-page":"e364","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","author":"Siontis B","year":"2015","unstructured":"Siontis B, Kumar S, Dispenzieri A, Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J 2015;5:e364."},{"key":"B31","series-title":"Leukemia","first-page":"417","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni E","year":"2016","unstructured":"Zamagni E, Nanni C, Gay F, 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 2016;30:417\u2013422."},{"key":"B32","series-title":"J Clin Oncol","first-page":"1606","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass J","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber MA, Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28:1606\u20131610."},{"key":"B33","series-title":"Leukemia","first-page":"1902","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz M","year":"2014","unstructured":"Merz M, Hielscher T, Wagner B, Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014;28:1902\u20131908."},{"key":"B34","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"555","article-title":"Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma","volume":"17","author":"van Beers EH","year":"2017","unstructured":"van Beers EH, van Vliet MH, Kuiper R, Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2017;17:555\u2013562."},{"key":"B35","series-title":"Lancet Oncol","first-page":"e293","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Merlini G, Bridoux F, Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol 2023;24:e293\u2013311."},{"key":"B36","series-title":"Lancet Oncol","first-page":"e538","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538\u2013548."},{"key":"B37","series-title":"Blood","first-page":"971","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau C","year":"2016","unstructured":"Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood 2016;127:971\u2013976."},{"key":"B38","series-title":"Haematologica","first-page":"1099","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition","volume":"102","author":"Granell M","year":"2017","unstructured":"Granell M, Calvo X, Garcia-Guinon A, Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 2017;102:1099\u20131104."},{"key":"B39","series-title":"J Clin Oncol","first-page":"3412","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp PR","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, International staging system for multiple myeloma. J Clin Oncol 2005;23:3412\u20133420."},{"key":"B40","series-title":"J Clin Oncol","first-page":"2863","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo A","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33:2863\u20132869."},{"key":"B41","series-title":"CA Cancer J Clin","first-page":"202","article-title":"Cancer statistics for African American\/Black people 2022","volume":"72","author":"Giaquinto AN","year":"2022","unstructured":"Giaquinto AN, Miller KD, Tossas KY, Cancer statistics for African American\/Black people 2022. CA Cancer J Clin 2022;72:202\u2013229."},{"key":"B42","article-title":"SEER Cancer Statistics Review, 1975-2016","author":"Howlader N","unstructured":"Howlader N, Noone A, Krapcho M, SEER Cancer Statistics Review, 1975-2016. Accessed December 1, 2025. Available at: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2016\/index.html"},{"key":"B43","series-title":"Blood Adv","first-page":"251","article-title":"Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy","volume":"8","author":"Peres LC","year":"2024","unstructured":"Peres LC, Oswald LB, Dillard CM, Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv 2024;8:251\u2013259."},{"key":"B44","series-title":"Blood Adv","first-page":"317","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz LE","year":"2023","unstructured":"Merz LE, Story CM, Osei MA, Absolute neutrophil count by Duffy status among healthy Black and African American adults. Blood Adv 2023;7:317\u2013320."},{"key":"B45","series-title":"Blood Adv","first-page":"1452","article-title":"Characterization of the phenotypic consequences of the Duffy-null genotype","volume":"9","author":"Hysong MR","year":"2025","unstructured":"Hysong MR, Shuey MM, Huffman JE, Characterization of the phenotypic consequences of the Duffy-null genotype. Blood Adv 2025;9:1452\u20131462."},{"key":"B46","series-title":"Semin Hematol","first-page":"38","article-title":"Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters","volume":"62","author":"Merz L","year":"2025","unstructured":"Merz L, Hartley-Brown M, Achebe M, Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters. Semin Hematol 2025;62:38\u201342."},{"key":"B47","series-title":"Lancet Reg Health Am","first-page":"100252","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"Turner BE","year":"2022","unstructured":"Turner BE, Steinberg JR, Weeks BT, Race\/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am 2022;11:100252."},{"key":"B48","series-title":"Blood","first-page":"3416","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder CB","year":"2010","unstructured":"Reeder CB, Reece DE, Kukreti V, Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115:3416\u20133417."},{"key":"B49","series-title":"Lancet Oncol","first-page":"431","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau P","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431\u2013440."},{"key":"B50","series-title":"Haematologica","first-page":"1925","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf B","year":"2012","unstructured":"Arnulf B, Pylypenko H, Grosicki S, Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97:1925\u20131928."},{"key":"B51","series-title":"Lancet Haematol","first-page":"e370","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos MV","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 2020;7:e370\u2013380."},{"key":"B52","series-title":"Blood","first-page":"Abstract 5557","article-title":"Assessing steroid toxicity in the elderly with multiple myeloma","volume":"134","author":"Nair V","year":"2019","unstructured":"Nair V, Mohammed H, Mahmood S, Assessing steroid toxicity in the elderly with multiple myeloma. Blood 2019;134(Suppl 1):Abstract 5557."},{"key":"B53","series-title":"Blood","first-page":"3027","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca A","year":"2021","unstructured":"Larocca A, Bonello F, Gaidano G, Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021;137:3027\u20133036."},{"key":"B54","series-title":"N Engl J Med","first-page":"301","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld P","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390:301\u2013313."},{"key":"B55","series-title":"Lancet Haematol","first-page":"e825","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation- eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees PM","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation- eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023;10:e825\u2013837."},{"key":"B56","series-title":"Blood Cancer J","first-page":"37","article-title":"Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Souto Filho JTD","year":"2025","unstructured":"Souto Filho JTD, Cantadori LO, Crusoe EQ, Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer J 2025;15:37."},{"key":"B57","series-title":"Lancet Haematol","first-page":"e810","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt H","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022;9:e810\u2013821."},{"key":"B58","series-title":"J Clin Oncol","first-page":"1279","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai EK","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E, Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2025;43:1279\u20131288."},{"key":"B59","series-title":"Blood","first-page":"679","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson PG","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679\u2013686."},{"key":"B60","series-title":"J Clin Oncol","first-page":"2712","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome","volume":"32","author":"Roussel M","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014;32:2712\u20132717."},{"key":"B61","series-title":"Blood","first-page":"4375","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar S","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375\u20134382."},{"key":"B62","series-title":"Lancet","first-page":"519","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open- label, phase 3 trial","volume":"389","author":"Durie BGM","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open- label, phase 3 trial. Lancet 2017;389:519\u2013527."},{"key":"B63","series-title":"Blood Cancer J","first-page":"53","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie BGM","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J 2020;10:53."},{"key":"B64","series-title":"Eur J Haematol","first-page":"110","article-title":"The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"104","author":"Okazuka K","year":"2020","unstructured":"Okazuka K, Ishida T, Nashimoto J, The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Eur J Haematol 2020;104:110\u2013115."},{"key":"B65","series-title":"Blood","first-page":"1801","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak AJ","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801\u20131809."},{"key":"B66","series-title":"J Clin Oncol","first-page":"Abstract e18568","article-title":"Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients","volume":"30","author":"Korde N","year":"2012","unstructured":"Korde N, Zingone A, Kwok M, Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. J Clin Oncol 2012;30:Abstract e18568."},{"key":"B67","series-title":"JAMA Oncol","first-page":"746","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde N","year":"2015","unstructured":"Korde N, Roschewski M, Zingone A, Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 2015;1:746\u2013754."},{"key":"B68","series-title":"Blood","first-page":"2513","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","volume":"136","author":"Jasielec JK","year":"2020","unstructured":"Jasielec JK, Kubicki T, Raje N, Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood 2020;136:2513\u20132523."},{"key":"B69","series-title":"Lancet Oncol","first-page":"1317","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar SK","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD, Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21:1317\u20131330."},{"key":"B70","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"S307","article-title":"MM-347: Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant: the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial","volume":"20","author":"Facon T","year":"2020","unstructured":"Facon T, Venner CP, Bahlis NJ, MM-347: Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant: the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial. Clin Lymphoma Myeloma Leuk 2020;20(Suppl 1):S307\u2013308."},{"key":"B71","series-title":"Blood","first-page":"3616","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon T","year":"2021","unstructured":"Facon T, Venner CP, Bahlis NJ, Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2021;137:3616\u20133628."},{"key":"B72","series-title":"JAMA Oncol","first-page":"862","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren O","year":"2021","unstructured":"Landgren O, Hultcrantz M, Diamond B, Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol 2021;7:862\u2013868."},{"key":"B73","series-title":"Blood Cancer J","first-page":"87","article-title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant","volume":"14","author":"Derman BA","year":"2024","unstructured":"Derman BA, Cooperrider J, Rosenblatt J, Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J 2024;14:87."},{"key":"B74","series-title":"J Clin Oncol","first-page":"2901","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa LJ","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2022;40:2901\u20132912."},{"key":"B75","series-title":"Lancet Haematol","first-page":"e890","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa LJ","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol 2023;10:e890\u2013901."},{"key":"B76","series-title":"Blood","first-page":"2029","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau C","year":"2024","unstructured":"Touzeau C, Perrot A, Hulin C, Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 2024;143:2029\u20132036."},{"key":"B77","series-title":"Blood","first-page":"Abstract 4","article-title":"Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay F","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood 2023;142:Abstract 4."},{"key":"B78","series-title":"J Clin Oncol","first-page":"26","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt LB","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol 2024;42:26\u201337."},{"key":"B79","series-title":"N Engl J Med","first-page":"425","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot A","year":"2025","unstructured":"Perrot A, Lambert J, Hulin C, Measurable residual disease-guided therapy in newly diagnosed myeloma. N Engl J Med 2025;393:425\u2013437."},{"key":"B80","series-title":"Leukemia","first-page":"1337","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder CB","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V, Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337\u20131341."},{"key":"B81","series-title":"J Clin Oncol","first-page":"Abstract 8516","article-title":"Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial","volume":"27","author":"Knop S","year":"2009","unstructured":"Knop S, Liebisch P, Wandt H, Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial. J Clin Oncol 2009;27(Suppl):Abstract 8516."},{"key":"B82","series-title":"Br J Haematol","first-page":"563","article-title":"Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma","volume":"167","author":"Reeder CB","year":"2014","unstructured":"Reeder CB, Reece DE, Kukreti V, Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol 2014;167:563\u2013565."},{"key":"B83","series-title":"Blood","first-page":"63","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen S","year":"2014","unstructured":"Bringhen S, Petrucci MT, Larocca A, Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014;124:63\u201369."},{"key":"B84","series-title":"Leukemia","first-page":"979","article-title":"Phase 1\/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma","volume":"32","author":"Bringhen S","year":"2018","unstructured":"Bringhen S, D\u2019Agostino M, De Paoli L, Phase 1\/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia 2018;32:979\u2013985."},{"key":"B85","series-title":"Haematologica","first-page":"1640","article-title":"Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I\/II studies","volume":"104","author":"Bringhen S","year":"2019","unstructured":"Bringhen S, Mina R, Petrucci MT, Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I\/II studies. Haematologica 2019;104:1640\u20131647."},{"key":"B86","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"433","article-title":"A multicenter, open-label, phase 1b study of carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients (CHAMPION-2)","volume":"17","author":"Boccia RV","year":"2017","unstructured":"Boccia RV, Bessudo A, Agajanian R, A multicenter, open-label, phase 1b study of carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients (CHAMPION-2). Clin Lymphoma Myeloma Leuk 2017;17:433\u2013437."},{"key":"B87","series-title":"Eur J Cancer","first-page":"89","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Grosicki S, J\u0119drzejczak WW, All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89\u201398."},{"key":"B88","series-title":"Lancet Oncol","first-page":"1503","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar SK","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol 2014;15:1503\u20131512."},{"key":"B89","series-title":"Br J Haematol","first-page":"492","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer H","year":"2019","unstructured":"Yimer H, Melear J, Faber E, Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 2019;185:492\u2013502."},{"key":"B90","series-title":"Br J Haematol","first-page":"176","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie B","year":"2007","unstructured":"Barlogie B, Anaissie E, van Rhee F, Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176\u2013185."},{"key":"B91","series-title":"Lancet Oncol","first-page":"1582","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon T","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:1582\u20131596."},{"key":"B92","series-title":"Leukemia","first-page":"942","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon T","year":"2025","unstructured":"Facon T, Moreau P, Weisel K, Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia 2025;39:942\u2013950."},{"key":"B93","series-title":"Lancet Oncol","first-page":"1323","article-title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","volume":"26","author":"Manier S","year":"2025","unstructured":"Manier S, Lambert J, Hulin C, Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial. Lancet Oncol 2025;26:1323\u20131333."},{"key":"B94","series-title":"Nat Med","first-page":"1366","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani SZ","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med 2025;31:1366\u20131202."},{"key":"B95","series-title":"N Engl J Med","first-page":"1597","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon T","year":"2024","unstructured":"Facon T, Dimopoulos M-A, Leleu XP, Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;391:1597\u20131609."},{"key":"B96","series-title":"Nat Med","first-page":"2235","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu X","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med 2024;30:2235\u20132241."},{"key":"B97","series-title":"Haematologica","first-page":"e162","article-title":"Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma","volume":"99","author":"Dytfeld D","year":"2014","unstructured":"Dytfeld D, Jasielec J, Griffith KA, Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica 2014;99:e162\u2013164."},{"key":"B98","series-title":"Blood","first-page":"Abstract 77","article-title":"Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232","volume":"110","author":"Zonder JA","year":"2007","unstructured":"Zonder JA, Crowley J, Hussein MA, Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232. Blood 2007;110:Abstract 77."},{"key":"B99","series-title":"Lancet Oncol","first-page":"29","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar SV","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29\u201337."},{"key":"B100","series-title":"N Engl J Med","first-page":"906","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker L","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906\u2013917."},{"key":"B101","series-title":"N Engl J Med","first-page":"1782","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal M","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782\u20131791."},{"key":"B102","series-title":"N Engl J Med","first-page":"1770","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy PL","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770\u20131781."},{"key":"B103","series-title":"Blood","first-page":"1597","article-title":"Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance","volume":"120","author":"Usmani SZ","year":"2012","unstructured":"Usmani SZ, Sexton R, Hoering A, Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012;120:1597\u20131600."},{"key":"B104","series-title":"Lancet Oncol","first-page":"333","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta- analysis of individual patient data","volume":"15","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta- analysis of individual patient data. Lancet Oncol 2014;15:333\u2013342."},{"key":"B105","series-title":"Haematologica","first-page":"363","article-title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma","volume":"101","author":"Dimopoulos MA","year":"2016","unstructured":"Dimopoulos MA, Cheung MC, Roussel M, Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica 2016;101:363\u2013370."},{"key":"B106","series-title":"J Clin Oncol","first-page":"3609","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin C","year":"2016","unstructured":"Hulin C, Belch A, Shustik C, Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol 2016;34:3609\u20133617."},{"key":"B107","series-title":"Blood","first-page":"Abstract 5751","article-title":"Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant eligible multiple myeloma patients","volume":"124","author":"Zepeda J","year":"2014","unstructured":"Zepeda J, HV, Duggan P, Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant eligible multiple myeloma patients. Blood 2014;124:Abstract 5751."},{"key":"B108","series-title":"J Clin Oncol","first-page":"3921","article-title":"Community-based Phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky R","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Community-based Phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol 2015;33:3921\u20133929."},{"key":"B109","series-title":"Blood","first-page":"Abstract 478","article-title":"Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study","volume":"118","author":"Niesvizky R","year":"2011","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. Blood 2011;118:Abstract 478."},{"key":"B110","series-title":"Br J Haematol","first-page":"222","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell EK","year":"2018","unstructured":"O\u2019Donnell EK, Laubach JP, Yee AJ, A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 2018;182:222\u2013230."},{"key":"B111","series-title":"Lancet Oncol","first-page":"801","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:801\u2013812."},{"key":"B112","series-title":"Blood Adv","first-page":"3721","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16","volume":"8","author":"Mollee P","year":"2024","unstructured":"Mollee P, Reynolds J, Janowski W, Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16. Blood Adv 2024;8:3721\u20133730."},{"key":"B113","series-title":"Blood Adv","first-page":"3129","article-title":"Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury","volume":"9","author":"Kim EB","year":"2025","unstructured":"Kim EB, Malespini JE, Lei M, Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury. Blood Adv 2025;9:3129\u20133135."},{"key":"B114","series-title":"Future Oncol","first-page":"131","article-title":"In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma","volume":"20","author":"Rifkin RM","year":"2024","unstructured":"Rifkin RM, Costello CL, Birhiray RE, In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. Future Oncol 2024;20:131\u2013143."},{"key":"B115","series-title":"Blood Cancer J","first-page":"147","article-title":"In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management","volume":"13","author":"Rifkin RM","year":"2023","unstructured":"Rifkin RM, Girnius SK, Noga SJ, In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management. Blood Cancer J 2023;13:147."},{"key":"B116","series-title":"Am J Hematol","first-page":"640","article-title":"Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial","volume":"86","author":"Kumar SK","year":"2011","unstructured":"Kumar SK, Lacy MQ, Hayman SR, Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011;86:640\u2013645."},{"key":"B117","series-title":"Blood","first-page":"Abstract 540","article-title":"Lenalidomide combined with cyclophosphamide and dexamethasone is effective and well tolerated induction treatment for newly diagnosed myeloma patients of all ages","volume":"122","author":"Pawlyn C","year":"2013","unstructured":"Pawlyn C, Brioli A, Gregory W, Lenalidomide combined with cyclophosphamide and dexamethasone is effective and well tolerated induction treatment for newly diagnosed myeloma patients of all ages. Blood 2013;122:Abstract 540."},{"key":"B118","series-title":"Haematologica","first-page":"1957","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson GH","year":"2021","unstructured":"Jackson GH, Davies FE, Pawlyn C, Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica 2021;106:1957\u20131967."},{"key":"B119","series-title":"Am J Hematol","first-page":"57","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar SV.","year":"2011","unstructured":"Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:57\u201365."},{"key":"B120","series-title":"J Clin Oncol","first-page":"587","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;32:587\u2013600."},{"key":"B121","series-title":"Lancet Oncol","first-page":"e328","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328\u2013346."},{"key":"B122","series-title":"J Clin Oncol","first-page":"1121","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker R","year":"2007","unstructured":"Walker R, Barlogie B, Haessler J, Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007;25:1121\u20131128."},{"key":"B123","series-title":"Blood","first-page":"2068","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel TB","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009;114:2068\u20132076."},{"key":"B124","series-title":"Clin Cancer Res","first-page":"4384","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni E","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 2015;21:4384\u20134390."},{"key":"B125","series-title":"J Clin Oncol","first-page":"2911","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study","volume":"35","author":"Moreau P","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol 2017;35:2911\u20132918."},{"key":"B126","series-title":"Leukemia","first-page":"1446","article-title":"Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn C","year":"2016","unstructured":"Pawlyn C, Fowkes L, Otero S, Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia 2016;30:1446\u20131448."},{"key":"B127","series-title":"Blood","first-page":"30","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche L","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 2017;130:30\u201334."},{"key":"B128","series-title":"Leukemia","first-page":"1713","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche L","year":"2019","unstructured":"Rasche L, Alapat D, Kumar M, Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 2019;33:1713\u20131722."},{"key":"B129","series-title":"JAMA Oncol","first-page":"28","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi NC","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 2017;3:28\u201335."},{"key":"B130","series-title":"N Engl J Med","first-page":"91","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal M","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91\u201397."},{"key":"B131","series-title":"N Engl J Med","first-page":"1875","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child JA","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875\u20131883."},{"key":"B132","series-title":"J Clin Oncol","first-page":"929","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie B","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929\u2013936."},{"key":"B133","series-title":"Blood","first-page":"731","article-title":"Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial","volume":"99","author":"Moreau P","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731\u2013735."},{"key":"B134","series-title":"J Clin Oncol","first-page":"9227","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand JP","year":"2005","unstructured":"Fermand JP, Katsahian S, Divine M, High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227\u20139233."},{"key":"B135","series-title":"N Engl J Med","first-page":"895","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371:895\u2013905."},{"key":"B136","series-title":"J Clin Oncol","first-page":"4621","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau JL","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621\u20134629."},{"key":"B137","series-title":"Blood","first-page":"9","article-title":"Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo M","year":"2012","unstructured":"Cavo M, Pantani L, Petrucci MT, Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9\u201319."},{"key":"B138","series-title":"N Engl J Med","first-page":"1311","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal M","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376:1311\u20131320."},{"key":"B139","series-title":"N Engl J Med","first-page":"132","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson PG","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387:132\u2013147."},{"key":"B140","series-title":"N Engl J Med","first-page":"2495","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal M","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495\u20132502."},{"key":"B141","series-title":"J Clin Oncol","first-page":"2434","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo M","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434\u20132441."},{"key":"B142","series-title":"Blood","first-page":"Abstract 2545","article-title":"Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial","volume":"106","author":"Sonneveld P","year":"2005","unstructured":"Sonneveld P, van der Holt B, Vellenga E, Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial. Blood 2005;106:Abstract 2545."},{"key":"B143","series-title":"Br J Haematol","first-page":"731","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai EK","year":"2016","unstructured":"Mai EK, Benner A, Bertsch U, Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol 2016;173:731\u2013741."},{"key":"B144","series-title":"J Clin Oncol","first-page":"1209","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences","volume":"28","author":"Barlogie B","year":"2010","unstructured":"Barlogie B, Attal M, Crowley J, Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010;28:1209\u20131214."},{"key":"B145","series-title":"Blood","first-page":"Abstract LBA-1","article-title":"Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem auto-HCT with Len maintenance (TAM) and AutoHCT with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 \u2013 StaMINA Trial)","volume":"128","author":"Stadtmauer A","year":"2016","unstructured":"Stadtmauer A, Pasquini M, Blackwell B, Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem auto-HCT with Len maintenance (TAM) and AutoHCT with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 \u2013 StaMINA Trial). Blood 2016;128:Abstract LBA-1."},{"key":"B146","article-title":"Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial","author":"Petrucci T","year":"2016","unstructured":"Petrucci T, Raimondo FD, Zamagni E, Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial. Presented at the 58th ASH Annual Meeting; December 3\u20136, 2016; San Diego, California."},{"key":"B147","series-title":"J Clin Oncol","first-page":"589","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer EA","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol 2019;37:589\u2013597."},{"key":"B148","series-title":"Biol Blood Marrow Transplant","first-page":"1638","article-title":"Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry","volume":"17","author":"Cook G","year":"2011","unstructured":"Cook G, Liakopoulou E, Pearce R, Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011;17:1638\u20131645."},{"key":"B149","series-title":"Bone Marrow Transplant","first-page":"417","article-title":"Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin RL","year":"2009","unstructured":"Olin RL, Vogl DT, Porter DL, Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417\u2013422."},{"key":"B150","series-title":"Leuk Lymphoma","first-page":"1442","article-title":"Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma","volume":"50","author":"Burzynski JA","year":"2009","unstructured":"Burzynski JA, Toro JJ, Patel RC, Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009;50:1442\u20131447."},{"key":"B151","series-title":"Haematologica","first-page":"141","article-title":"The role of second autografts in the management of myeloma at first relapse","volume":"91","author":"Alvares CL","year":"2006","unstructured":"Alvares CL, Davies FE, Horton C, The role of second autografts in the management of myeloma at first relapse. Haematologica 2006;91:141\u2013142."},{"key":"B152","series-title":"Leuk Lymphoma","first-page":"1455","article-title":"Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation","volume":"52","author":"Fenk R","year":"2011","unstructured":"Fenk R, Liese V, Neubauer F, Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011;52:1455\u20131462."},{"key":"B153","series-title":"Lancet Oncol","first-page":"874","article-title":"High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial","volume":"15","author":"Cook G","year":"2014","unstructured":"Cook G, Williams C, Brown JM, High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:874\u2013885."},{"key":"B154","series-title":"Lancet Haematol","first-page":"e340","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook G","year":"2016","unstructured":"Cook G, Ashcroft AJ, Cairns DA, The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol 2016;3:e340\u2013351."},{"key":"B155","series-title":"Bone Marrow Transplant","first-page":"413","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"Kumar S","year":"2008","unstructured":"Kumar S, Mahmood ST, Lacy MQ, Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008;42:413\u2013420."},{"key":"B156","series-title":"Eur J Haematol","first-page":"209","article-title":"Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994\u20132004","volume":"85","author":"Vangsted AJ","year":"2010","unstructured":"Vangsted AJ, Klausen TW, Andersen NF, Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994\u20132004. Eur J Haematol 2010;85:209\u2013216."},{"key":"B157","series-title":"Leukemia","first-page":"986","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"Kumar SK","year":"2018","unstructured":"Kumar SK, Dispenzieri A, Fraser R, Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 2018;32:986\u2013995."},{"key":"B158","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"445","article-title":"Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma","volume":"20","author":"Kastritis E","year":"2020","unstructured":"Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma. Clin Lymphoma Myeloma Leuk 2020;20:445\u2013452."},{"key":"B159","series-title":"Br J Haematol","first-page":"551","article-title":"Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma","volume":"193","author":"Bygrave C","year":"2021","unstructured":"Bygrave C, Pawlyn C, Davies F, Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol 2021;193:551\u2013555."},{"key":"B160","series-title":"Leuk Lymphoma","first-page":"2200","article-title":"Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation","volume":"54","author":"Auner HW","year":"2013","unstructured":"Auner HW, Szydlo R, Rone A, Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma 2013;54:2200\u20132204."},{"key":"B161","series-title":"Biol Blood Marrow Transplant","first-page":"773","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival","volume":"18","author":"Jimenez-Zepeda VH","year":"2012","unstructured":"Jimenez-Zepeda VH, Mikhael J, Winter A, Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012;18:773\u2013779."},{"key":"B162","series-title":"Cancer","first-page":"2438","article-title":"Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients","volume":"119","author":"Sellner L","year":"2013","unstructured":"Sellner L, Heiss C, Benner A, Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer 2013;119:2438\u20132446."},{"key":"B163","series-title":"Cancer","first-page":"3549","article-title":"Durable remission with salvage second autotransplants in patients with multiple myeloma","volume":"118","author":"Shah N","year":"2012","unstructured":"Shah N, Ahmed F, Bashir Q, Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012;118:3549\u20133555."},{"key":"B164","series-title":"Semin Oncol","first-page":"74","article-title":"High-dose therapy in multiple myeloma and primary amyloidosis: an overview","volume":"26","author":"Kyle RA.","year":"1999","unstructured":"Kyle RA. High-dose therapy in multiple myeloma and primary amyloidosis: an overview. Semin Oncol 1999;26:74\u201383."},{"key":"B165","series-title":"Lancet Oncol","first-page":"293","article-title":"Management of multiple myeloma: a systematic review and critical appraisal of published studies","volume":"4","author":"Kumar A","year":"2003","unstructured":"Kumar A, Loughran T, Alsina M, Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003;4:293\u2013304."},{"key":"B166","series-title":"Biol Blood Marrow Transplant","first-page":"4","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review","volume":"9","author":"Hahn T","year":"2003","unstructured":"Hahn T, Wingard JR, Anderson KC, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 2003;9:4\u201337."},{"key":"B167","series-title":"Bone Marrow Transplant","first-page":"923","article-title":"Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives","volume":"34","author":"Zeiser R","year":"2004","unstructured":"Zeiser R, Bertz H, Spyridonidis A, Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant 2004;34:923\u2013928."},{"key":"B168","series-title":"Bone Marrow Transplant","first-page":"1135","article-title":"Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"37","author":"van de Donk NW","year":"2006","unstructured":"van de Donk NW, Kroger N, Hegenbart U, Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1135\u20131141."},{"key":"B169","series-title":"Blood","first-page":"4362","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst HM","year":"2004","unstructured":"Lokhorst HM, Wu K, Verdonck LF, The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103:4362\u20134364."},{"key":"B170","series-title":"J Clin Oncol","first-page":"3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst HM","year":"2000","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031\u20133037."},{"key":"B171","series-title":"Blood","first-page":"4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst HM","year":"1997","unstructured":"Lokhorst HM, Schattenberg A, Cornelissen JJ, Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997;90:4206\u20134211."},{"key":"B172","series-title":"Bone Marrow Transplant","first-page":"1179","article-title":"Donor leukocyte infusions for multiple myeloma","volume":"26","author":"Salama M","year":"2000","unstructured":"Salama M, Nevill T, Marcellus D, Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179\u20131184."},{"key":"B173","series-title":"Blood","first-page":"1196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot G","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S, Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196\u20131198."},{"key":"B174","series-title":"Leukemia","first-page":"659","article-title":"Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma","volume":"18","author":"Ayuk F","year":"2004","unstructured":"Ayuk F, Shimoni A, Nagler A, Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004;18:659\u2013662."},{"key":"B175","series-title":"Blood Adv","first-page":"5988","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi NC","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 2020;4:5988\u20135999."},{"key":"B176","series-title":"J Clin Oncol","first-page":"2540","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX study","volume":"31","author":"Rawstron AC","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM, Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX study. J Clin Oncol 2013;31:2540\u20132547."},{"key":"B177","series-title":"Biol Blood Marrow Transplant","first-page":"S4","article-title":"Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study","volume":"25","author":"Hahn TE","year":"2019","unstructured":"Hahn TE, Wallace PK, Fraser R, Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study. Biol Blood Marrow Transplant 2019;25:S4\u20136."},{"key":"B178","series-title":"Eur J Haematol","first-page":"416","article-title":"Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma","volume":"85","author":"Putkonen M","year":"2010","unstructured":"Putkonen M, Kairisto V, Juvonen V, Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 2010;85:416\u2013423."},{"key":"B179","series-title":"Lancet Haematol","first-page":"e431","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein SA","year":"2017","unstructured":"Holstein SA, Jung SH, Richardson PG, Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 2017;4:e431\u2013442."},{"key":"B180","series-title":"J Clin Oncol","first-page":"3279","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy PL","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 2017;35:3279\u20133289."},{"key":"B181","series-title":"Blood","first-page":"2413","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers E","year":"2011","unstructured":"Kneppers E, van der Holt B, Kersten MJ, Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011;118:2413\u20132419."},{"key":"B182","series-title":"Biol Blood Marrow Transplant","first-page":"1183","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina M","year":"2014","unstructured":"Alsina M, Becker PS, Zhong X, Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:1183\u20131189."},{"key":"B183","series-title":"N Engl J Med","first-page":"1759","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo A","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759\u20131769."},{"key":"B184","series-title":"Leukemia","first-page":"1853","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt H","year":"2020","unstructured":"Goldschmidt H, Mai EK, Durig J, Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 2020;34:1853\u20131865."},{"key":"B185","series-title":"Ann Oncol","first-page":"228","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto P","year":"2017","unstructured":"Musto P, Anderson KC, Attal M, Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017;28:228\u2013245."},{"key":"B186","series-title":"Lancet Oncol","first-page":"1705","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay F","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021;22:1705\u20131720."},{"key":"B187","series-title":"Blood","first-page":"Abstract 79","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 24 months of maintenance","volume":"138","author":"Laubach JP","year":"2021","unstructured":"Laubach JP, Kaufman JL, Sborov DW, Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 24 months of maintenance. Blood 2021;138(Suppl 1):Abstract 79."},{"key":"B188","series-title":"J Clin Oncol","first-page":"Abstract 7501","article-title":"Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained MRD negativity in the phase 3 PERSEUS trial","volume":"43","author":"Moreau P","year":"2025","unstructured":"Moreau P, Sonneveld P, Einseke H, et al. Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained MRD negativity in the phase 3 PERSEUS trial. J Clin Oncol 2025;43(Suppl):Abstract 7501."},{"key":"B189","series-title":"Blood","first-page":"300","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros A","year":"2025","unstructured":"Badros A, Foster L, Anderson LD, Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood 2025;145:300\u2013310."},{"key":"B190","series-title":"Leukemia","first-page":"690","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka AK","year":"2014","unstructured":"Nooka AK, Kaufman JL, Muppidi S, Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014;28:690\u2013693."},{"key":"B191","series-title":"J Clin Oncol","first-page":"1928","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph NS","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 2020;38:1928\u20131937."},{"key":"B192","series-title":"J Clin Oncol","first-page":"2946","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld P","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol 2012;30:2946\u20132955."},{"key":"B193","series-title":"Blood","first-page":"4647","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist UH","year":"2013","unstructured":"Mellqvist UH, Gimsing P, Hjertner O, Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013;121:4647\u20134654."},{"key":"B194","series-title":"Lancet Oncol","first-page":"1378","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau P","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:1378\u20131390."},{"key":"B195","series-title":"Lancet Oncol","first-page":"1003","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau P","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 2024;25:1003\u20131014."},{"key":"B196","series-title":"Lancet","first-page":"253","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393:253\u2013264."},{"key":"B197","series-title":"Leukemia","first-page":"3019","article-title":"Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma","volume":"34","author":"Goldschmidt H","year":"2020","unstructured":"Goldschmidt H, Dimopoulos MA, Rajkumar SV, Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia 2020;34:3019\u20133027."},{"key":"B198","series-title":"J Clin Oncol","first-page":"4030","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos MA","year":"2020","unstructured":"Dimopoulos MA, Spicka I, Quach H, Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol 2020;38:4030\u20134041."},{"key":"B199","series-title":"Blood","first-page":"Abstract 1656","article-title":"Interim analyses of overall survival (OS) from the TOURMALINE MM3 & MM4 studies of ixazomib maintenance following primary therapy in multiple myeloma (MM)","volume":"138","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Rajkumar SV, Lonial S, Interim analyses of overall survival (OS) from the TOURMALINE MM3 & MM4 studies of ixazomib maintenance following primary therapy in multiple myeloma (MM). Blood 2021;138(Suppl 1):Abstract 1656."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/1\/article-e260001.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/1\/article-e260001.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/1\/article-e260001.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:58:05Z","timestamp":1767887885000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/1\/article-e260001.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":398,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0001","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}